Vibrant Therapeutics
Vibrant Therapeutics Raises $61M Series B | Logic-Gated Cancer Immunotherapy
Vibrant Therapeutics Closes $61M for Cancer Immunotherapy
Vibrant Therapeutics, developing logic-gated cancer immunotherapies that activate only in tumor microenvironments, has raised $61 million in Series B funding.
The round was co-led by Pfizer Ventures and Apricot Capital with participation from Bayland Capital and Northern Light Venture Capital.
Key Highlights
- Strategic backing from Pfizer Ventures
- Logic-gated immunotherapy platform
- Tumor microenvironment activation
Company Overview
Vibrant Therapeutics is pioneering logic-gated cancer immunotherapies designed to activate specifically in tumor microenvironments, potentially reducing systemic toxicity while enhancing anti-tumor efficacy.
Company Info
Investors (3)
Share
Related Reports
Tebra Raises $250M Growth Financing | Healthcare Practice Management Platform
Healthcare practice management platform Tebra secures $250 million in growth financing led by Hildred Capital for AI-driven automation.
Harmattan AI Raises $200M Series B | Defense Tech Unicorn at $1.4B Valuation
French defense tech company Harmattan AI secures $200 million Series B led by Dassault Aviation, reaching unicorn status.
AirNexis Therapeutics Raises $200M Series A | Novel COPD Treatment
Biotech AirNexis Therapeutics emerges from stealth with $200 million Series A for dual PDE3/4 inhibitor COPD therapy.
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free